Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Acadia, adjunctive, adjunctively, aforementioned, akathisia, Allergan, AMPA, antecedent, antipsychotic, apathy, Arbitrage, Ariosa, aripiprazole, Arizona, arm, arriving, article, aspartate, AstraZeneca, atypical, Bachelor, Baylor, bend, BioCardia, biofilm, bolstering, Cephalon, cessation, CGM, Chardan, ChemTrak, cholesterol, chorea, Circuit, clarifying, classification, CMC, cognition, Computershare, CTNI, departure, diagnostic, Diego, disorientation, distributionrestricted, disturbance, Division, double, Dow, dry, DuPont, dyskinesia, dysregulation, edema, eleven, emotion, Empery, enGene, England, EPS, exigent, Fava, Fischer, Gerard, Gin, Goldberg, Hal, Harvard, herewith, Hoe, home, Hospital, infused, injection, interior, IntraCellular, JAMA, Jerry, Jersey, John, Lane, Laughren, lessee, lifecycle, Livionex, Loyola, LP, macular, Mangement, Matthew, Maurizio, MBA, memory, MGH, Michael, Mintz, modest, Mountainview, mouth, necessity, NEJM, Neuroendocrinology, Neuropsychiatry, noncash, nonrecurring, Norac, notably, Nuvora, Oculex, Ono, Osteo, partly, Pharmatek, piece, Plaza, plc, PLTG, PPD, PPVA, PreferredCertificate, propelling, psychiatry, psychopharmacology, puruant, QC, Quest, rapastinel, renowned, River, Rockefeller, Rush, Ryan, Sabby, Saddle, Sanacora, Sanjay, Sanofi, se, Septermber, Sequenom, sexual, Shire, sit, sleep, Smith, smooth, solution, sore, SSRI, straight, syndrome, Syntex, Syva, tardive, Teva, therefrom, Thermo, topline, twenty, unblinded, unconsummated, uncontrolled, Underwriting, underwritten, Upper, USPTO, vi, VTGN, WallachBeth, withhold, WO, workload, wound, Yale
Removed:
absent, acceleration, albumin, anniversary, arrhythmia, assistance, astemizole, auditory, Australia, behave, biographical, BLA, bladder, boardroom, BPM, breakdown, BS, CA, cadaver, cancel, CDN, charge, cisapride, closed, commit, committed, computational, confirming, consenting, consisted, constituted, countervailing, default, define, deter, devoted, directorship, diversity, documented, dramatically, earliest, ease, effected, efficiency, endeavor, endocrine, endoderm, enrich, enzyme, epiblast, ES, experimentally, familiarity, fat, fate, flat, formalized, freedom, gland, greatly, gut, hereof, Hong, humanized, incumbent, inducing, influencing, inheritable, inside, insulin, integral, integrity, interdisciplinary, Japan, Kong, Korean, lawful, leasing, lidocaine, lifespan, Lonza, lung, mandatorily, marker, MDSCC, mesendoderm, mesoderm, modifying, month, mRNA, MSSM, neuroectoderm, nifedipine, nominee, opposite, organic, patenting, penalty, pink, plastic, pluripotency, pluripotential, powerful, precisely, predispose, prefer, premise, prominence, properly, propose, propranolol, protected, PTO, pure, quotation, ratifying, reelection, replace, reporter, reprogrammed, reprogramming, restructured, rifampicin, satisfied, secretion, sertindole, shareholder, signature, Singapore, solid, sorting, sotalol, speed, stead, step, stimulate, subjective, substitute, tendered, tenure, therewith, thing, thyroid, Trillium, true, UC, uncured, upcoming, urea, vacancy, validate, verapamil, view, waive, WHEREOF, woman
Filing tables
Filing exhibits
- 10-K Annual report
- 10.112 Indemnification Agreement Effective April 8, 2016 Between the Company and Jerry B. Gin
- 10.116 Second Amendment to Employment Agreement by and Between Vistagen Therapeutics, Inc. and Shawn K. Singh
- 10.117 Second Amendment to Employment Agreement by and Between Vistagen Therapeutics, Inc. and H. Ralph Snodgrass, PH.D.,
- 23.1 Consent of Independent Registered Public Accouting Firm
- 31.1 Certification of the Company's Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 Certification of the Company's Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32.1 Certification of the Company's Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
VTGN similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of VistaGen Therapeutics, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:
(i) the accompanying Annual Report on Form 10-K of the Company for the annual period ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
June 24, 2016
/s/ Shawn K. Singh
Shawn K. Singh, JD
Principal Executive Officer
/s/ Jerrold D. Dotson
Jerrold D. Dotson
Principal Financial Officer